도파민운반체 영상의 파킨슨증 감별진단 성능: (123)I-FP-CIT SPECT 연구 = The Discriminating Nature of Dopamine Transporter Image in Parkinsonism: The Competency of Dopaminergic Transporter Imaging Differential Diagnosis of Parkinsonism: (123)I-FP-CIT SPECT Study

참고문헌 (Reference)

1 Niznik HB, "The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus" 1991;56192-8

2 Niznik HB, "The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus" 1991;56192-8

3 Perneczky R, "The Alzheimer Variant of Lewy Body Disease: A Pathologically Confirmed Case-Control Study" 20 : 89-94, 2005

4 Walker Z, "Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison" 60 : 1568-1572, 2004

5 McKeith IG, "Spectrum of Parkinson′s disease, Parkinson′s dementia, and Lewy body dementia" 18 : 865-902, 2000

6 Whone AL, "Slower progression of Parkinson′s disease with ropinirole versus levodopa: The REAL-PET study" 54 : 93-101, 2003

7 Kaufman MJ, "Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson′s diseased striatum" 1991;9;43-9

8 Kaufman MJ, "Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson′s disease striatum" 43-9, 1991;9

9 Kim SE, "Serotonin transporters in the midbrain of Parkinson′s disease patients: a study with 123I-beta-CIT SPECT" 44 : 870-876, 2003

10 Pizzolato G, "Reduced striatal dopamine receptors in Alzheimer′s disease: single photon emission tomography study with the D2 tracer [123I]-IBZM" 47 : 1065-1068, 1996

11 Nurmi E, "Rate of progression in Parkinson′s disease: a 6-[18F]fluoro-L-dopa PET study" 16 : 608-615, 2001

12 Nurmi E, "Progression in Parkinson′s disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT" 47 : 804-808, 2000

13 de Rijk MC, "Prevalence of parkinsonism and Parkinsons disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinsons disease" 62 : 10-15, 1997

14 Ceravolo R, "Presynaptic nigro-striatal function in a group of Alzheimer′s disease patients with parkinsonism: evidence from a dopamine transporter imaging study" 111 : 1065-1073, 2004

15 Kemppainen N, "PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD" 55 : 205-209, 2000

16 Morrish PK, "Measuring the rate of progression and estimating the preclinical period of Parkinson′s disease with [18F]dopa PET" 64 : 314-319, 1998

17 Tissingh G, "Iodine-123-N-omega-fluoropropyl-2β-carbomethoxy- 3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson′s disease" 39 : 1143-1148, 1998

18 Hughes AJ, "Improved accuracy of clinical diagnosis of Lewy body Parkinson′s disease" 57 : 1497-1499, 2001

19 Booij J, "Imaging of dopamine transporters with Iodine-123-FPCIT SPECT in healthy controls and patients with Parkinson′s disease" 39 : 1879-1884, 1998

20 Neumeyer JL, "High affinity SPECT radiotracer of monoamine reuptake sites in brain" 4 3144-6, 1991;34

21 Mayeux R, "Heterogeneity in dementia of the Alzheimer type evidence of subgroups" 453-61, 1985;35

22 Colloby S, "Functional imaging in Parkinson′s disease and dementia with Lewy bodies" 17 : 158-163, 2004

23 Lavalaye J, "Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers" 27 : 867-869, 2000

24 Van Laere K, "Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis" 47 : 384-392, 2006

25 Van Laere K, "Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template- based discriminant analysis" 47 : 384-392, 2006

26 O′Brien JT, "Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies" 61 : 919-925, 2004

27 Jeon B, "Dopamine transporter imaging with [123I]--CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson′s disease" 65 : 60-64, 1998

28 Kosaka K, "Diffuse Lewy body disease within the spectrum of Lewy body disease" New York, Cambridge University Press 238-247, 1996

29 Walker Z, "Differentiation of dementia with Lewy bodies from Alzheimer′s disease using a dopaminergic presynaptic ligand" 73 : 134-140, 2002

30 Chui HC, "Clinical subtypes of dementia of the Alzheimer type" 1544-50, 1985;35

31 Donnemiller E, "Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease" 24 : 320-325, 1997

32 Morrish PK, "An [18F]dopa-PET and clinical study of the rate of progression in Parkinson′s disease" 119 : 585-591, 1996

33 Benamer TS, "Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group" 15 : 503-510, 2000

34 Hughes AJ, "Accuracy of clinical diagnosis of idiopathic Parkinson′s disease: a clinico-pathological study of 100 cases" 1992;55181-4

35 Parkinson Study Group, "A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism" 55 : 1540-1547, 2000

36 Wang J, "18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson′s disease in various Hoehn & Yahr stages" 254 : 185-190, 2007

37 Booij J, "123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP- lesioned monkeys" 27 : 183-190, 1997

38 Booij J, "123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson′s disease" 62 : 133-140, 1997

39 Winogrodzka A, "123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson′s disease" 108 : 1011-1019, 2001